key: cord-0840820-iymmf4k6
authors: Vijayvargiya, Prakhar; Garrigos, Zerelda Esquer; Castillo Almeida, Natalia E.; Gurram, Pooja R.; Stevens, Ryan W.; Razonable, Raymund R.
title: Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
date: 2020-04-30
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2020.04.027
sha: 4af3e50a061f1e6204c3442c4a37c1077d341333
doc_id: 840820
cord_uid: iymmf4k6

Abstract The novel severe acute respiratory syndrome coronavirus 2 is causing a worldwide pandemic that may lead to a highly morbid and potentially fatal coronavirus disease-19 (COVID-19). There is currently no drug that has been proven as an effective therapy for COVID-19. Several candidate drugs are being considered and evaluated for treatment. This includes clinically-available drugs, such as chloroquine, hydroxychloroquine, and lopinavir/ritonavir, which are being repurposed for the treatment of COVID-19. Novel experimental therapies, such as remdesivir and favipiravir, are also actively being investigated for antiviral efficacy. Clinically-available and investigational immunomodulators, such as the IL-6 inhibitors tocilizumab and sarilumab and the anti-GMCSF lenzilumab, are being tested for their anticipated effect in counteracting the pro-inflammatory cytokine environment that characterizes severe and critical COVID-19. This review article examines the evidence behind the potential use of these leading drug candidates for the treatment of COVID-19. The authors conclude, based on this review, that there is still no high-quality evidence to support any of these proposed drug therapies. The authors, therefore, encourage the enrollment of eligible patients to multiple ongoing clinical trials that assess the efficacy and safety of these candidate therapies. Until the results of controlled trials are available, none of the suggested therapeutics is clinically proven as an effective therapy for COVID-19.

This review article examines the evidence behind the potential use of these leading drug candidates for the treatment of COVID-19. The authors conclude, based on this review, that there is still no high-quality evidence to support any of these proposed drug therapies. The authors, therefore, encourage the enrollment of eligible patients to multiple ongoing clinical trials that assess the efficacy and safety of these candidate therapies. Until the results of controlled trials are available, none of the suggested therapeutics is clinically proven as an effective therapy for COVID-19. The infection caused by SARS-CoV-2 manifests as Coronavirus disease 2019 . The majority of patients infected with SARS-CoV-2 either remain asymptomatic or demonstrate mild symptoms and recover from their illness. The most common clinical presentation is pneumonia with symptoms of fever, dry cough, and shortness of breath. 3 Anosmia, dysgeusia, and diarrhea have been reported. 4 About 20-30% of patients require intensive care for respiratory support, and over 15% of patients with severe pneumonia develop acute respiratory distress syndrome (ARDS) (Figure   1 ). 5, 6 There is currently no proven drug for the treatment of COVID-19. The standard of care is supportive measure, aimed at managing fever, dehydration, and constitutional and other clinical symptoms. Because of the morbid and potentially fatal nature of COVID-19, there have been efforts to repurpose other clinically available drugs based upon antiviral activities that have either been demonstrated in vitro or proposed due to the agents' mechanism of action. Novel and experimental drugs with potential antiviral properties are also being considered. Finally, therapies that modulate the hyperinflammatory response of the host are being investigated (Table) . Antiviral drugs are believed to be useful early in the course of the disease when it is mediated by active viral replication. Immunomodulating agents are generally being evaluated for use during the later pro-inflammatory process, usually manifesting as clinical deterioration in the second week after symptom onset.

In this article, we aim to provide an objective review of the evidence behind the proposed drug therapies for COVID-19. Electronic search in PubMed, LitCovid, Embase, Google Scholar, and clinicaltrials.gov databases was conducted. Search terms included SARS-CoV-2, COVID-19, 2019-nC0V, and individual drug names. Manuscripts published in English were reviewed and relevant references were checked. The information in this review is only as current as of the time this article is written (April 16, 2020), since new data is anticipated to emerge during this rapidly evolving pandemic.

Based on the currently available information, healthcare institutions are encouraged to create local protocols based on available resources. A hypothetical protocol that may serve as a starting point is depicted in Figure 2 .

Chloroquine is an aminoquinoline antimalarial drug discovered in 1934. 29 In addition to antimalarial activity, it has antiviral, anti-inflammatory, and immunomodulatory effects. These properties have led to its use in inflammatory rheumatologic diseases. Various mechanisms have been proposed for its antiviral activity (Table) . Chloroquine can rapidly increase the endosomal pH, thereby reducing the fusion between SARS-CoV-2 and the endosome. By impairing terminal glycosylation of angiotensin-converting enzyme 2 (ACE2), it decreases the affinity of SARS-CoV-2 with ACE2, which serves as its main entry point into the cell. patients remain positive for SARS-CoV-2 PCR on day 5-6 after treatment initiation. 13 In another study that is yet to be peer-reviewed, clinical improvement was observed in 25/31 (80.6%) of patients treated with hydroxychloroquine as compared to 17/31 (54.8%) in the control group that received standard treatment (including antivirals other than hydroxychloroquine). 14 Collectively, the suggestion of clinical benefit for the use of chloroquine and hydroxychloroquine for SARS-CoV-2 should be interpreted with caution, as it is supported only by limited, and often times conflicting, clinical data.

Accordingly, the use of chloroquine or hydroxychloroquine for COVID-19 should be under clinical trials or treatment registries, and their off-label use outside of these trials is not currently recommended.

Before starting hydroxychloroquine or chloroquine, patients should have corrected QT (QTc) measured. 40 Certain patient groups need to be tested for glucose-6phosphate dehydrogenase (G6PD) deficiency, which is associated with hemolytic anemia with chloroquine use. While chloroquine and hydroxychloroquine are considered safe, the therapeutic index for chloroquine is narrow, and it has been associated with gastrointestinal symptoms, retinopathy and deafness/tinnitus, as well as life-threatening toxicity, including cardiomyopathy and arrhythmias and methemoglobinemia. 41, 42 Several clinical trials are underway to provide real-world clinical data on the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19 (Supplemental Table) . 10 Based on the current limited data, strong recommendations for widespread off-label clinical use cannot be made. However, the United States (US) Food and Drug Administration (FDA) has issued an emergency use authorization of chloroquine and hydroxychloroquine to treat hospitalized patients with Clinicians considering the use of these agents are advised to enroll their patients in clinical trials. In the event that trial participation is not possible, careful consideration of the risks versus potential benefits is emphasized. Detailed information on these clinical trials is available in the Supplemental Table and on clinicaltrials.gov. 28

Favipiravir is a non-nucleoside RNA polymerase inhibitor that was developed for the treatment of influenza. It has also been tested against Ebola, Marburg, Nipah, Lassa fever and Zika viruses. [44] [45] [46] Favipiravir was used alone or in combination with monoclonal antibodies as post-exposure prophylaxis for Ebola in at least five healthcare workers. 47 Its use, in combination with ribavirin, potentiated its effect in vitro. 46, 48 There is very limited published in vitro and clinical data on the use of favipiravir in coronavirus infections. In a study that was previously shared prior to peer-review but has since been temporarily removed, favipiravir and lopinavir/ritonavir (LPV/r) were compared in an open-label study of 80 patients during the current SARS-CoV-2 pandemic in China. 15 When compared to LPV/r, favipiravir was associated with shorter time to viral clearance (median 4 versus 11 days, p<0.001) and significant improvement in chest imaging (improvement rate 91.43% versus 62.22%, p=0.004). Additionally, the Japanese Health Ministry commented that the use of favipiravir in 70-80 patients did not produce similar clinical benefit. 49 These contrasting findings call for a randomized controlled trial to assess the safety and efficacy of favipiravir for the treatment of COVID-19 (Table) . although it showed weak antiviral activity. 50 In a subsequent study of 41 patients who received LPV/r or standard of care, there was a significant difference in the incidence of ARDS or mortality at day 21 (LPV/r = 2.4% versus control = 28.8%, p<0.001). A multivariate analysis showed that lack of LPV/r use was independently associated with worse outcomes. Notably, ribavirin was used concurrently with LPV/r because of its known broad-spectrum antiviral activity and possibly an indirect immunomodulatory demonstrated that combination of arbidol with LPV/r was significantly better than LPV/r alone for nasopharyngeal swab PCR conversion to negative after seven days (75% versus 35%, p<0.05), after 14 days (94% versus 52.9%, p<0.05) and improvement on CT chest (69% versus 29%, p<0.05). 22 However, in a randomized controlled open-label study, LPV/r combination was not significantly better than the standard of care for the management of severe COVID-19. 21 This randomized controlled trial has some noteworthy limitations. First, the mortality rate was high, which suggests the enrolment of patients with severe COVID-19. Second, the median time from symptom onset to randomization was 13 days, which suggests the drug may have been given too late, when viral replication may no longer be the major factor. Notably, a total of 42% of patients remained positive at day 28, raising the concern about its antiviral efficacy. An absolute difference of 6.8% in 28-day mortality was observed, but this did not reach statistical significance. Collectively, the data on the use of LPV/r for the treatment of COVID-19 is very limited. Larger controlled clinical studies are needed to evaluate the role of LPV/r (potentially in combination with ribavirin) in COVID-19 (Table) .

Remdesivir is an investigational nucleoside analog that works as an RNA-chain terminator by inhibiting RNA-dependent viral RNA polymerase. It is a monophosphoramidate prodrug of adenosine C-nucleoside 59 , and its structure is similar to tenofovir alafenamide, which is active against HIV and hepatitis B virus. 60 Europe, including three who received remdesevir. 68 One of these three, a 31-year-old patient, discontinued remdesivir on day 5 of therapy due to elevated alanine aminotransferase, but recovered. A second, 48-year-old patient, received 10 days of therapy and recovered, and a third, 80-year-old patient, received 10 days of therapy but died on day 24.

The study of 53 patients who received compassionate remdesivir for severe COVID-19 showed improvement in the oxygen status of 36 (68%) patients. 25 The reported mortality rate was 13%, which is lower than the anticipated mortality rate of severe COVID-19, albeit the variability in supportive care and available resources could also account for the difference in mortality. Moreover, the results of this cohort study are limited by the lack of a control group, the exclusion of 8 (13%) patients from the final analysis, and a relatively small sample size. There are several ongoing and expanding randomized controlled trials to evaluate the safety and antiviral activity in patients with COVID-19. Currently, the use of remdesivir is restricted to controlled clinical trials, although it is also available through an expanded access program and a compassionate use program for individuals who are not eligible to participate in controlled clinical trials.

Only results of these controlled clinical trials will provide the data on its true efficacy and safety.

Based on in vitro data, it is known that remdesivir has wide therapeutic index, high genetic barrier to resistance and long intracellular half-life. 39, 60, 61 Remdesivir is also highly selective for viral polymerases and has a low propensity for human toxicity.

Gilead has now stopped supplying remdesivir for compassionate use in adults but has opened an expanded access program. Most of its drug supply is now reserved for patients enrolled in several ongoing randomized controlled trials. The dose in clinical trials is 200mg intravenous (IV) on day 1 followed by 100 mg IV daily for a total of 5 or 10 day course (Table) .

Several compounds that are also being proposed, but with much more limited experimental or clinical data, are nitazoxanide (an antiparasitic drug with broadspectrum antiviral activity), ribavirin (a broad-spectrum antiviral drug), baloxavir (an antiinfluenza drug that is undergoing clinical trials in China), among many others. Data on these drugs are scant and very limited and will not be discussed further in this review.

A pro-inflammatory stage of COVID-19 that often presents later in the course of infection is believed to be mediated by cytokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 6 (IL-6). This is clinically manifested by the development of severe pneumonia leading to ARDS and the requirement for mechanical ventilation. 69 This pro-inflammatory storm is associated with a high risk of multi-organ failure and mortality. Accordingly, there has been an interest in the use of pharmacologic compounds directed against these cytokines.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is believed to be a key cytokine mediator of the pro-inflammatory state in patients with COVID-19. While there has been no clinical data on its use in patients with COVID-19, mechanistically, blocking the GM-CSF pathway is expected to reduce the severity of cytokine-induced inflammation. Based on this, a randomized controlled clinical trial is planned to assess the efficacy and safety of lenzilumab, a humaneered recombinant monoclonal antibody against GM-CSF. Lenzilumab has undergone Phase I and II studies when it was assessed for the treatment of cytokine release syndrome associated with CAR-T therapy. Riovant Sciences also announced that they developed an anti-GM-CSF monoclonal antibody (Gimsilumab) to treat COVID-19 patients with ARDS. Gimsilumab has been tested in Phase I study of healthy volunteers (results unpublished). Binding of the monoclonal antibody to GM-CSF receptor will block the signaling pathway that leads to cytokine release syndrome, which is also believed to characterize the proinflammatory stage of COVID-19.

Severe COVID-19 patients are characterized by a higher baseline IL-6 level compared to non-severe infections. 70 In critically ill patients with COVID-19, IL-6 levels were almost tenfold higher. 71 Higher IL-6 level is closely associated with SARS-CoV-2 RNAaemia. 71 While it is not clear whether elevation in IL-6 has a causal association with pro-inflammatory damage of the lungs or is just a consequence of the lung infection, attempts at blocking IL-6 by using monoclonal antibodies directed against IL-6 receptors have garnered interested as a potential therapeutic option.

Tocilizumab is a humanized monoclonal antibody that is used to manage cytokine release syndrome associated with CAR-T therapy. Sarilumab is a human IgG1 monoclonal antibody approved for the treatment of rheumatoid arthritis. These IL-6 blockers bind to soluble and membrane-bound IL-6 receptors. A clinical trial involving sarilumab for the treatment of severe COVID-19 is ongoing, where the efficacy and safety of sarilumab 200 mg and 400 mg dose administered intravenously over 1 hour, are being compared with standard of care (Table) . Since measurement of IL-6 levels is not readily available in most institutions, C-reactive protein (CRP) levels may be used as surrogate markers of the increased pro-inflammatory state. IL-6 inhibitors rapidly decrease CRP levels after administration, and therefore, CRP levels may be used to monitor the response to therapy. (Table) .

It is important to reiterate that blocking IL-6 receptors may curb fever and inflammation, but this approach also blunts the host defense against infection. IL-6 inhibition is associated with increased risk of infections, albeit this is more common after chronic use and in combination with other immunosuppressive drugs. Ongoing clinical trials are excluding patients with active or untreated tuberculosis and systemic bacterial and fungal infections.

The US FDA has approved the emergency investigational use of convalescent plasma for the treatment of critically ill patients with COVID-19. 72 Convalescent plasma is collected from COVID-19 recovered individuals who are eligible for blood donation.

The traditional screening protocol for blood donation should be satisfied. In addition, the plasma should be collected from people with a prior confirmed diagnosis of COVID-19 who have resolved their symptoms at least 14 days prior to donation. In addition, they should have negative PCR for SARS-CoV-2 and high SARS-CoV-2 neutralizing antibody titers. Takeda pharmaceutical company is also developing an anti-SARS-CoV-2 polyclonal hyperimmune globulin (TAK-888).

The use of convalescent plasma resulted in a shorter hospital stay and reduced mortality in SARS 73 and H1N1 influenza. 74 It has also been used during Ebola and MERS outbreaks. 75 A preliminary report of a series of five patients with severe COVID-19 pneumonia complicated by ARDS showed that administration of convalescent plasma containing neutralizing antibody (SARS-CoV-2 IgG titers greater than 1:1000 by ELISA and neutralizing antibody titer >40) led to clinical improvement. 27 There was a normalization of body temperature in four patients within three days, the sequential organ failure assessment score (SOFA) decreased, and viral load declined to negativity by day 12. ARDS resolved within 12 days in four patients. These preliminary findings are promising, but the small number and the uncontrolled nature of this study calls for further evaluation of this treatment modality in randomized controlled clinical trials.

Several groups, including investigators from our institution and other academic institutions, are collaborating to achieve a common goal of developing convalescent plasma as a viable treatment of critically ill patients with COVID-19.

To date, there is no proven effective drug or immunomodulator therapy for the management of COVID-19. As this SARS-CoV-2 pandemic escalates, the search for an effective treatment regimen is at the forefront of clinical medicine and research.

Two major approaches are being actively pursued. First, strategies directed against the virus have led to the use of repurposed drugs (such as chloroquine, hydroxychloroquine, LPV/r and ribavirin) and novel investigational compounds (such as favipiravir and remdesivir). We do not yet know which, if any, of these compounds will eventually be proven effective against SARS-COV-2. Thus, the collaboration of the healthcare community to engage patients for participation in clinical trials is essential. In addition to the single-center and multi-center trials, the World Health Organization recently embarked on a large mega-trial that will compare the clinical outcome of patients treated with chloroquine or hydroxychloroquine, LPV/r and remdesivir. Second, there are numerous clinical trials that are aimed to determine if curbing the proinflammatory state produced during COVID-19 with drugs such as IL-6 inhibitors (e.g., sarilumab or tocilizumab) or anti-GM-CSF compounds (e.g., lenzilumab and gimsilumab) will lead to better clinical outcomes by preventing or reversing ARDS and multi-organ failure.

Touret 

An interactive web-based dashboard to track COVID-19 in real time

Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Guide to Understanding the 2019 Novel Coronavirus

Anosmia, Hyposmia, and Dysgeusia Symptoms of Coronavirus Disease

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses

Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever

Ebola virus disease: an update on post-exposure prophylaxis. The Lancet Infectious Diseases

Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses

Japanese flu drug 'clearly effective' in treating coronavirus, says China

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study

Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Arguments in favour of remdesivir for treating SARS-CoV-2 infections

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Late Ebola virus relapse causing meningoencephalitis: a case report

First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease

Controlled Trial of Ebola Virus Disease Therapeutics

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Clinical and virological data of the first cases of COVID-19 in Europe: a case series. The Lancet Infectious Diseases

Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus

The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. medRxiv

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. medRxiv

Treatment of severe acute respiratory syndrome